Scarica l'app Stockscreener
3.03
1.94%
-0.06
Dopo l'orario di chiusura:
3.03
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché CAMP Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$3.09
Aprire:
$3.12
Volume 24 ore:
28,756
Relative Volume:
0.64
Capitalizzazione di mercato:
$61.09M
Reddito:
$264.74M
Utile/perdita netta:
$-49.71M
Rapporto P/E:
-0.7398
EPS:
-4.0959
Flusso di cassa netto:
$-43.55M
1 W Prestazione:
-29.37%
1M Prestazione:
-32.52%
6M Prestazione:
+657.50%
1 anno Prestazione:
+11.81%
Intervallo 1D:
$3.01
$3.3041
Intervallo di 1 settimana:
$3.01
$4.378
Portata 52W:
$0.3901
$12.30
Camp 4 Therapeutics Corp Stock (CAMP) Company Profile
Nome
Camp 4 Therapeutics Corp
Settore
Industria
Telefono
617-651-8867
Indirizzo
ONE KENDALL SQUARE, CAMBRIDGE, CA
Confronta CAMP con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CAMP
Camp 4 Therapeutics Corp
|
3.03 | 61.09M | 264.74M | -49.71M | -43.55M | -4.0959 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.62 | 121.88B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
573.45 | 62.69B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
555.11 | 33.86B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
235.74 | 30.51B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
238.51 | 25.69B | 3.81B | -644.79M | -669.77M | -6.24 |
Camp 4 Therapeutics Corp Stock (CAMP) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-11-05 | Iniziato | JP Morgan | Overweight |
| 2024-11-05 | Iniziato | Piper Sandler | Overweight |
| 2024-11-05 | Iniziato | William Blair | Outperform |
| 2022-08-16 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2021-12-22 | Downgrade | Craig Hallum | Buy → Hold |
| 2021-09-24 | Reiterato | Craig Hallum | Buy |
| 2021-06-25 | Reiterato | Craig Hallum | Buy |
| 2020-12-18 | Downgrade | JP Morgan | Neutral → Underweight |
| 2020-04-17 | Aggiornamento | Jefferies | Hold → Buy |
| 2020-03-05 | Reiterato | Craig Hallum | Buy |
| 2019-12-20 | Reiterato | Craig Hallum | Buy |
| 2019-12-20 | Downgrade | First Analysis Sec | Outperform → Neutral |
| 2019-06-28 | Aggiornamento | Northland Capital | Market Perform → Outperform |
| 2019-05-29 | Downgrade | Goldman | Neutral → Sell |
| 2019-05-01 | Reiterato | Craig Hallum | Buy |
| 2019-03-25 | Downgrade | JP Morgan | Overweight → Neutral |
| 2019-01-25 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-12-21 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2018-12-14 | Reiterato | B. Riley FBR | Buy |
| 2018-12-11 | Downgrade | First Analysis Sec | Strong Buy → Outperform |
| 2018-12-11 | Downgrade | Northland Capital | Outperform → Market Perform |
| 2018-11-27 | Iniziato | Goldman | Neutral |
| 2018-10-15 | Iniziato | Jefferies | Hold |
| 2018-09-28 | Reiterato | Craig Hallum | Hold |
| 2018-04-27 | Reiterato | Craig Hallum | Hold |
| 2018-03-08 | Downgrade | Craig Hallum | Buy → Hold |
| 2018-02-16 | Aggiornamento | First Analysis Sec | Equal-Weight → Overweight |
Mostra tutto
Camp 4 Therapeutics Corp Borsa (CAMP) Ultime notizie
Manasa Pamboor holds free camp for physiotherapy, speech therapy and counseling - Daijiworld
Free Camp for Physiotherapy, Speech Therapy, and Counselling at Manasa Pamboor - Mangalorean.com
CAMP4 Therapeutics Advances RNA-Based Therapeutics - TipRanks
Promising Developments and Solid Financials Support Buy Rating for CAMP4 Therapeutics - TipRanks
CAMP4 Reports Full Year 2024 Financial Results and Provides Corporate Update - Yahoo Finance
Gunnison Copper Provides a Construction Update for the Johnson Camp Mine in Southeast Arizona - Yahoo Finance
CAMP4 Appoint Doug E. Williams, Ph.D., and Murray Stewart, DM FRCP To Board - citybiz
Camp4 Therapeutics expands board with two new directors By Investing.com - Investing.com Australia
Camp4 Therapeutics expands board with two new directors - Investing.com
CAMP4 Therapeutics Expands Board with New Director Appointments - TipRanks
Major Leadership Boost: CAMP4 Adds Drug Development Pioneers to Board - StockTitan
CAMP4 Appoints Multiple Industry Veterans to its Board of Directors - Yahoo Finance
Stocks Turn Mixed as Magnificent Seven Stocks Fall - TradingView
Stocks Supported by Strength in Chip Stocks and Lower Bond Yields - TradingView
SMALL CAP IDEA: 'Flu Camp' rapid drug trial firm slashes big pharma costs - This is Money
Orchid Isle Dance Announces Connection Camp in Hawaii: Adventure Travel for the Social Dancer - Yahoo Finance
Stocks Rebound as US Government Shutdown Seems Averted - TradingView
It Might Not Be A Great Idea To Buy Camping World Holdings, Inc. (NYSE:CWH) For Its Next Dividend - Yahoo Finance
KY House passes bill to protect conversion therapy, reverse Beshear’s executive order - Lexington Herald Leader
CAMP4 Therapeutics Corporation (CAMP): Among Penny Stocks with Insider Buying in 2025 - Insider Monkey
12 Penny Stocks with Insider Buying in 2025 - Insider Monkey
Home | Department of Parks and Recreation - City and County of Honolulu (.gov)
(PDF) Combination Therapy in Pulmonary Arterial Hypertension—Targeting the Nitric Oxide and Prostacyclin Pathways - ResearchGate
RFK's plan to make America healthy again? Send people with mental health conditions to farms - Yahoo
12 Health Care Stocks Moving In Tuesday's Pre-Market Session - Benzinga
Fox Chase Cancer Center to Hold Fifth Annual Cancer Epigenetics Symposium - Fox Chase Cancer Center
CAMP4 to Participate in Upcoming Investor Conferences - The Manila Times
3 Key Healthcare Conferences Where CAMP4 Therapeutics Will Share Its regRNA Innovation - StockTitan
Trump to prepare facility at Guantanamo for 30,000 migrants - Reuters
Modest Final Quarter Completes Shaky Biotech IPO Comeback For 2024 - News & Insights
Top regulator calls for ban on wilderness camps in North Carolina - WBTV
CAMP4 to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
CAMP4 Therapeutics CEO to Present Corporate Update at J.P. Morgan Healthcare Conference - StockTitan
Here are 71 Mass. life science firms presenting at J.P. Morgan - The Business Journals
CAMP4 Provides Corporate Updates and Highlights Key Upcoming Milestones - The Manila Times
Strategic Investment Boosts Exploration Plans in Ontario's Gold Camp - Streetwise Reports
Camp4 Therapeutics sees MAD safety and key biomarker data in 2H25 - TipRanks
CAMP4 Therapeutics Advances Urea Cycle Disorder Drug After $82M IPO, Secures BioMarin Partnership - StockTitan
CAMP4 Therapeutics Reports Positive Safety Data from CMP-CPS-001 Phase 1 Study and Highlights Key 2025 Milestones - Nasdaq
CeriBell Shares Rise 47% to Lead Trio of Life Sciences IPOs - MSN
CAMP4 Appoints John Maraganore and Rachel Meyers as Strategic Advisors - citybiz
CAMP4 Therapeutics Taps Former Alnylam CEO, RNA Pioneer to Drive Next-Gen Gene Therapy Platform - StockTitan
Why DocuSign Shares Are Trading Higher By Around 14%; Here Are 20 Stocks Moving Premarket - Benzinga
Upstream Bio Leads Life Sciences IPOs With Upsized Listing - MSN
CAMP4 to Participate in the Piper Sandler 36th Annual Healthcare Conference - The Manila Times
CAMP4 Therapeutics to Present at Piper Sandler Healthcare Conference in NYC | CAMP Stock News - StockTitan
Meet the Newest Stock in the Nasdaq. It's Soared 918% Since Last Year, and It's Still a Buy Right Now, According to Certain Wall Street Analysts. - The Motley Fool
CAMP4 Reports Third Quarter 2024 Financial Results - The Manila Times
CAMP4 Therapeutics Corporation (CAMP) reports earnings - Quartz
Camp4 Therapeutics Corporation Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
CAMP4 Therapeutics Secures $370M BioMarin Deal, Raises $82M in IPO Milestone | CAMP Stock News - StockTitan
Camp 4 Therapeutics Corp Azioni (CAMP) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):